The availability for human experimentation of an inhibitor of the enzyme aldose reductase (alrestatin) affords the opportunity to test the hypothesis that sorbitol intervenes in the development of diabetic peripheral neuropathy.1.2 Furthermore, it provides a potential pharmacologic approach to the prevention of peripheral neuropathy and other complications in diabetes mellitus. In this study, we report the effects of alrestatin on ten patients with diabetic peripheral neuropathy.
Ten patients entered the study after their informed consent was obtained. Selected patients were of both sexes, between the ages of 43 and 67 years, and had had diabetes for a mean duration of 14.4 years. On admission to the hospital, they were instructed to continue taking their usual fixed-calorie diet, insulin doses, and oral antidiabetic agents.Physical examinations and laboratory tests were performed before the study was begun and immediately on its completion. The following battery of laboratory tests was performed: ECG
Culebras A, Alió J, Herrera J, López-Fraile MIP. Effect of an Aldose Reductase Inhibitor on Diabetic Peripheral Neuropathy: Preliminary Report. Arch Neurol. 1981;38(2):133–134. doi:10.1001/archneur.1981.00510020091017
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: